Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
62 hedge funds and large institutions have $101M invested in Sorrento Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 20 reducing their positions, and 7 closing their positions.
303% more call options, than puts
Call options by funds: $730K | Put options by funds: $181K
40% more capital invested
Capital invested by funds: $72M → $101M (+$28.8M)
0% more funds holding
Funds holding: 62 → 62 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
20% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.72M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.07M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$489K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$228K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$198K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.57M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$835K |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
-$568K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$371K |
| 5 |
Baird Financial Group
Milwaukee,
Wisconsin
|
-$327K |
SRNE Hedge Fund Activity: Q3 2016 in Review
62 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q3 2016, worth a combined $101M — up 40% from $72M a quarter earlier.
Fund positioning in SRNE was balanced in Q3 2016: 7 funds opened new positions, 7 closed out, 16 added to existing stakes and 20 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.72M. The largest seller was Sabby Management, cutting an estimated $1.57M.
- 62 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $101M of Sorrento Therapeutics, Inc. stock for Q3 2016, up 40% quarter-over-quarter.
- 7 funds opened new Sorrento Therapeutics, Inc. positions in Q3 2016 and 7 closed out, a net change of 0 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q3 2016 was Vanguard Group, an estimated $3.72M added.
- The largest Sorrento Therapeutics, Inc. seller in Q3 2016 was Sabby Management, an estimated $1.57M sold.
Based on aggregated 13F filings for Q3 2016.